Price movement over the last 24 hours
Alcon AG vs Petróleo Brasileiro SA — how do they compare? Alcon AG trades at $66.79 (market cap $32.69B), while Petróleo Brasileiro SA trades at $17.16 (market cap $102.10B). The key difference: Petróleo Brasileiro SA is far larger — about 3.1× Alcon AG's market cap, and Petróleo Brasileiro SA pays the higher dividend (10.58%). Which is the better fit depends on your goals.
| ALC | PBR | |
|---|---|---|
Market Cap | $32.69B | $102.10B |
Sector | Health | Technology |
52-Week High | $92.22 | $22.03 |
52-Week Low | $62.02 | $11.54 |
Enterprise Value | $36.28B | $164.64B |
Dividend Yield | 0.54% | 10.58% |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
PBR trades at $16.26, up 0.93% with a bearish technical outlook despite strong fundamentals. The company reported $488.72B revenue and $107.58B net income for 2025, with attractive valuation metrics including a 5.18 P/E ratio and 24.94% ROE. Recent earnings showed mixed results with a Q1 2026 miss but strong beats in previous quarters. Analyst consensus remains positive with a $23.90 price target, while technical indicators show bearish momentum with key support at $16.
PBR presents a compelling value opportunity with deep discount valuation and robust cash flow generation supporting substantial dividends. However, recent earnings volatility and bearish technical signals suggest near-term pressure. The stock's 46% upside to consensus target offers significant potential, but investors should monitor execution on production growth targets and global oil price stability as key catalysts.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Petróleo Brasileiro S.A., commonly known as Petrobras, is a state-controlled Brazilian multinational corporation in the oil and gas industry. The company is one of the world's largest producers of oil and gas, primarily operating in exploration, production, refining, and power generation. Petrobras is particularly known for its deep-sea and ultra-deep-sea exploration and production activities in the vast pre-salt offshore reserves, which are a major component of Brazil's economy.
Read more on PBR →